Close menu

March 23rd, 2022 | 10:47 CET

Stocks that change the world: TeamViewer, Perimeter Medical, Nordex

  • Technology
Photo credits:

When new technology meets the right opportunity, things can go up quickly for companies. One example is the German company TeamViewer, which already had an established remote desktop solution that many users had heard of when the pandemic broke out. When we moved to the home office overnight but had to use software from the office, it made sense to install TeamViewer. Innovative solutions are also meeting with great demand in other industries. We analyze what this means for investors.

time to read: 3 minutes | Author: Nico Popp

Table of contents:

    TeamViewer: What will happen in May?

    Although TeamViewer was quickly considered the pandemic stock par excellence in March 2020, the value has lost since then. So, what had happened? On the one hand, a private equity firm divested some of its shares, and on the other, TeamViewer failed to turn the hype into good numbers. However, for a few months now, TeamViewer has been a comeback candidate. The Company is becoming better known, and there are some links to larger companies, such as SAP. A few months ago, the research portal wrote of an "interesting purchase candidate" with a view to the market capitalization: "Now that the Göppingen-based Company is already cooperating with the software giant from Walldorf, a takeover by SAP, including a stay in Germany, would be obvious. Such technology is currently still missing from the major corporation's portfolio."

    TeamViewer plans to present figures at the beginning of May. Since potential buyers do not want to tie themselves down, takeover speculation is only likely to speed up after better figures. The fact that private equity firm Permira is still on board with TeamViewer also fits the picture: the investment professionals know how to prepare exits. They are probably already turning the right screws to make TeamViewer more attractive. As the share is still trading below its high for the year and new potential is emerging above it, the stock should not be missing from any watchlist.

    Perimeter Medical: Technology against cancer

    Perimeter Medical Imaging is a company that looks similar today to what TeamViewer did before investors got involved. The Canadian company has made it its business to offer solutions around cancer operations that, on the one hand, increase patient well-being and, at the same time, save costs. For example, when tissue is removed during breast cancer surgery, doctors send it to pathology, and there it is examined for cancer cells. If the surgical procedure was thorough, further treatment steps begin; otherwise, there is a risk of follow-up surgery. It is precisely here where Perimeter Medical Imaging comes into play. The Company enables surgeons to directly analyze tissue in laboratory quality at the operating table. The results are available before the patient is sutured - so if necessary, further tissue can be taken, and a follow-up operation is prevented.

    Perimeter Medical Imaging's technology has been approved by the US Food and Drug Administration. Clinical trials are expected to be completed by the end of 2022 at a breast cancer center in Houston, Texas. The Company estimates a USD 3.7 billion market for its innovation and talks of potentially high margins. In addition to breast cancer, the approach to detecting tissue abnormalities could offer benefits in other use cases - the underlying AI technology is flexible, after all, and only needs to be fed the appropriate data. Since December, the stock has lost about 50% of its value and is just getting ready to exit the downtrend. The Company is at an early stage, but the opportunities are obvious. The market is open to new methods against cancer.

    Nordex: Figures still not right

    Even if renewable energies have always seemed sensible: Wind power and photovoltaics have never been as hip as they are today. Climate change is seen as a threat to humanity. In addition, just a few hours' flight east of us, an autocrat can invade a neighboring country and bully his own population thanks to lavish oil and gas billions. These are good conditions for the Rostock-based wind turbine manufacturer Nordex. The reduction of bureaucracy around approval procedures for wind turbines and power lines, which has already been announced for Germany anyway, is likely to be pursued with even more verve given the new situation. Nevertheless, the trees are not growing to the sky for Nordex. The reason lies in the Company's weak margin, which stood at around 1% at the end of last year - too little for the capital market. Rising energy prices and the associated transport costs are not making the outlook for Nordex any better.

    For this reason, too, the stock has halted its recovery rally. Only when the figures for the Rostock-based company are also right is the market likely to push the share up again. However, Nordex is operating in a promising area. The situation with Nordex is similar to that with TeamViewer: once companies have reached a certain size and implemented a mature business model, the market wants to see results. Perimeter Medical, on the other hand, is in a different phase: the growth company has a promising product and is testing it in trials this year. In such market phases, the market usually focuses on opportunities rather than getting lost in the small details of quarterly figures.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Fabian Lorenz on May 17th, 2022 | 14:14 CEST

    Nel share with a tailwind, but what are TeamViewer and Aspermont doing?

    • Technology
    • Digitization

    Last week was disastrous for many technology stocks. In this environment, the Nel share showed strength and yesterday, it also performed positively in a relatively weak environment. That is because there is currently a tailwind for the hydrogen specialist from a wide variety of places: analysts, the European Union and even a king. At least analysts are also convinced of Aspermont. After the positive figures, investors are hoping for new impetus from the technology company's presentation at a virtual investor conference. At TeamViewer, analyst comments are mixed, but the price targets are attractive.


    Commented by Nico Popp on May 16th, 2022 | 12:48 CEST

    Future Tech check: BASF, Meta Materials, BYD, Rock Tech Lithium

    • metamaterials
    • Technology

    What will drive share prices in the future is more uncertain than ever. The sword of Damocles of the recession is currently hovering over many future topics. But should long-term investors be driven by fear of recession? On the contrary! Now is the best time to consider investments for the future. The good thing is that thorough due diligence can pay off twice over. First, it increases the chances of hitting the bull's eye, and second, the prices may even suit investors. We take a closer look at three shares!


    Commented by André Will-Laudien on May 10th, 2022 | 11:54 CEST

    GreenTech stocks are on the rise! Buy now: BASF, Meta Materials, Nordex, Siemens Energy

    • GreenTech
    • Technology
    • Investments

    The distortions on the capital markets can hardly be topped at the moment. The nickel price has risen by 300%, only to drop by 70% again. And all this in only 48 hours. There are countless examples in the current stock market environment that are historically unparalleled. In just 2 months, the Bund Future fell from 178 to 151, a loss of 16% in the 10-year Bund. In parallel, the capital market interest rate rose from minus 0.45% to a whopping plus 1.15%. So interest rates are back, inflation is spreading, and supply deficits continue to fuel the underlying stagflation scenario! One major trend should bounce back after the end of the many corrections: GreenTech! Here is a selection of interesting stocks.